Motixafortide: complete guide

Motixafortide is a cyclic peptide CXCR4 inhibitor approved by FDA as Aphexda in 2023 to mobilize stem cells in multiple myeloma. This guide covers its structure, mechanism, trial and warnings.

Complete guide5 min read

Key takeaway

FDA approved motixafortide as Aphexda on September 8, 2023, for use with filgrastim in multiple myeloma. PubChem lists a molecular weight of 2,159.5 g/mol. In the GENESIS trial, 67.5% of Aphexda patients reached the label’s cell collection goal, versus 9.5% on placebo.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Aphexda on September 8, 2023.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited1 in this article · 1 across 1 article on Motixafortide
Related productsBPC-157, TB-500 and thymic peptides

Motixafortide is a synthetic cyclic peptide that blocks CXCR4, a receptor that helps hold blood stem cells in the bone marrow. Releasing that hold moves stem cells into the blood, where they can be collected for transplant. This guide covers its structure, mechanism, labeled use, pivotal trial and label warnings. Sources were checked on November 17, 2026.

Quick answer: Motixafortide is a prescription CXCR4 inhibitor sold as Aphexda. Its label covers mobilizing blood stem cells, together with filgrastim, for collection and autologous transplant in people with multiple myeloma. It has no boxed warning. Label warnings include anaphylactic shock and other allergic reactions.

Vitrapep does not sell motixafortide; this page is a reference summary of published research and regulatory information.

What is motixafortide?

The Aphexda label calls motixafortide acetate “a synthetic, cyclic peptide composed of a sequence of amino acids.” It gives a molecular weight of 2159.6 g/mol as the free base (Aphexda label, 2023). PubChem lists the formula as C97H144FN33O19S2 and the weight as 2,159.5 g/mol (PubChem CID 91865076).

ChEBI text in PubChem calls it “a heterodetic cyclic peptide,” meaning its ring is closed by a bond other than a normal peptide bond. MeSH describes it as “a T140 analog and CXCR4 antagonist.” It was developed under the code BL-8040. Our guide to types of peptides explains cyclic peptides.

Drugs@FDA lists the original approval of Aphexda (NDA 217159) on September 8, 2023. The applicant now shown is Ayrmid Pharma (Drugs@FDA). DailyMed lists Aphexda labels from BioLineRx USA and from Gamida Cell.

Table 1

Motixafortide: key facts

Fact Detail
Structure type Synthetic heterodetic cyclic peptide; T140 analog; acetate salt
Class CXCR4 inhibitor (hematopoietic stem cell mobilizer)
Molecular formula C97H144FN33O19S2
Molecular weight 2,159.5 g/mol (2,159.6 per label, free base)
First FDA approval September 8, 2023 (Aphexda, NDA 217159)
Brand names (US) Aphexda

How does motixafortide work?

Blood-forming stem cells live in the bone marrow. The receptor CXCR4 pairs with a signal called SDF-1α, or CXCL12. The label says the two “play a role in the trafficking and homing” of stem cells to the marrow. Once there, CXCR4 “can help anchor these cells to the marrow matrix.”

The label states that motixafortide “is an inhibitor of the C-X-C Motif Chemokine Receptor 4 (CXCR4)” and blocks the binding of SDF-1α. With the anchor released, stem cells move into the circulating blood. The label reports that treatment raised white cell counts and circulating stem and progenitor cells in mice, rats, dogs and humans. In a rodent transplant model, mobilized cells could engraft with long-term repopulating capacity (Aphexda label, 2023).

The label pairs motixafortide with filgrastim, a granulocyte colony-stimulating factor (G-CSF). DrugBank text in PubChem notes that motixafortide works like plerixafor, another CXCR4 inhibitor.

What is motixafortide approved for?

The Aphexda label states that it is indicated “in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood.” The purpose is “collection and subsequent autologous transplantation in patients with multiple myeloma.”

Autologous means the transplant uses the patient’s own stem cells. The collection procedure is called apheresis.

What did the key trials show?

GENESIS. The pivotal human trial was a phase 3, randomized, double-blind, placebo-controlled study at 18 sites in five countries. It randomized 122 adults with multiple myeloma two to one: 80 to motixafortide plus filgrastim and 42 to placebo plus filgrastim. The goal was to collect a set number of CD34+ stem cells within up to two apheresis sessions.

The label reports that 67.5% of Aphexda patients reached the collection goal, compared with 9.5% on placebo. The adjusted difference was 56.8 percentage points (p < 0.0001) (Aphexda label, 2023). The published report used the trial’s own end point and found 92.5% versus 26.2%. In a single apheresis session, 88.8% versus 9.5% reached the goal (Crees et al., 2023). The registry record is NCT03246529.

What side effects does the label list?

The Aphexda label has no boxed warning. Its most common adverse reactions, each above 20%, are listed below. Several are “site” reactions, meaning where the drug is given.

  • Site reactions (73% versus 0% with placebo), site pain (53% versus 5%), site erythema and site pruritus
  • Pruritus (itching)
  • Flushing
  • Back pain

The label’s warnings cover anaphylactic shock and hypersensitivity reactions, site reactions and leukocytosis, a high white cell count. They also cover tumor cell mobilization in patients with leukemia, a potential for tumor cell mobilization in general, and embryo-fetal toxicity. The published GENESIS report described the most common events as short-lived, grade 1 or 2 site reactions (Crees et al., 2023).

What is motixafortide’s regulatory status, and how is it used in research?

Motixafortide is a prescription drug in the United States. Drugs@FDA lists Aphexda as a prescription product. ChEBI text in PubChem notes that FDA granted it orphan drug designation for pancreatic cancer in 2019.

Research continues in human studies beyond myeloma. Washington University School of Medicine completed a phase 1 study pairing it with natalizumab for sickle cell gene therapy (NCT05618301). St. Jude Children’s Research Hospital lists a recruiting phase 1 study of stem cell mobilization in sickle cell disease (NCT06442761). A phase 2 pancreatic cancer study at Columbia University is active (NCT04543071). We found no documented role as a routine laboratory reagent in the sources we checked.

Frequently asked questions about motixafortide

Is motixafortide a peptide?

Yes. The label calls it a synthetic, cyclic peptide, and ChEBI classes it as a heterodetic cyclic peptide.

When was motixafortide approved?

Drugs@FDA lists the original approval of Aphexda on September 8, 2023.

How is motixafortide different from plerixafor?

DrugBank text in PubChem says both work by inhibiting CXCR4. Motixafortide is a cyclic peptide, a T140 analog.

Is motixafortide used alone?

No. Its label indication is in combination with filgrastim (G-CSF).

Does motixafortide have a boxed warning?

No. Its warnings include anaphylactic shock, site reactions and possible tumor cell mobilization.

What to know now

  • Structure: synthetic heterodetic cyclic peptide; T140 analog; C97H144FN33O19S2; 2,159.5 g/mol.
  • Approval: Aphexda, September 8, 2023; prescription only.
  • Mechanism: blocks CXCR4 and SDF-1α binding, releasing stem cells from the marrow.
  • Label use: with filgrastim, stem cell mobilization for autologous transplant in multiple myeloma.
  • Evidence: 67.5% versus 9.5% reached the label’s collection goal in GENESIS.
  • Safety: no boxed warning; site reactions most common; anaphylactic shock is a listed warning.

What we’re watching

Results of the sickle cell disease mobilization studies (NCT05618301, NCT06442761) and the Columbia pancreatic cancer study (NCT04543071). Related guides: types of peptides, rusfertide and enfuvirtide.

More for immune system

All 24 compounds for immune system

Sources: BioLineRx USA Inc 2023, APHEXDA (motixafortide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 217159 (APHEXDA) . Retrieved November 17, Drugs@FDA: NDA 217159 (APHEXDA); National Center for Biotechnology Information 2026, PubChem compound summary for CID 91865076, motixafortide; Crees 2023, Nature Medicine, 29; BioLineRx 2017; Washington University School of Medicine 2022; St. Jude Children’s Research Hospital 2024, SCD stem cell mobilization and apheresis using motixafortide; Columbia University 2020. All 8 citations

Back to the research library

References

  1. BioLineRx USA Inc. (2023). APHEXDA (motixafortide) prescribing information (revised 9/2023). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7cdc584-ebf0-a68e-e053-6294a90a9ea9
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 217159 (APHEXDA). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217159
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 91865076, motixafortide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/91865076
  4. Crees, Z. D., et al. (2023). Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: A randomized phase 3 trial. Nature Medicine, 29(4), 869-879. https://doi.org/10.1038/s41591-023-02273-z
  5. BioLineRx, Ltd. (2017). A phase III, safety, tolerability and efficacy of combination treatment of BL-8040 and granulocyte colony stimulating factor (G-CSF) as compared to placebo and G-CSF for the mobilization of hematopoietic stem cells for autologous transplantation in subjects with multiple myeloma (MM) (GENESIS) (ClinicalTrials.gov ID NCT03246529). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03246529
  6. Washington University School of Medicine. (2022). Motixafortide and natalizumab to mobilize CD34+ hematopoietic stem cells for gene therapies in sickle cell disease (SCD) (ClinicalTrials.gov ID NCT05618301). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05618301
  7. St. Jude Children’s Research Hospital. (2024). SCD stem cell mobilization and apheresis using motixafortide (ClinicalTrials.gov ID NCT06442761). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT06442761
  8. Columbia University. (2020). Chemo4METPANC combination chemokine inhibitor, immunotherapy, and chemotherapy in pancreatic adenocarcinoma (ClinicalTrials.gov ID NCT04543071). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04543071